Erdafitinib 4mg Tablets

Product Introduction

Erdafitinib 4mg is an oral targeted cancer medicine containing erdafitinib, an FGFR kinase inhibitor. It is used for adults with locally advanced or metastatic urothelial cancer that has susceptible FGFR genetic alterations and has progressed after prior systemic therapy, according to oncology protocols and local approval. Patients need tumor testing for FGFR alterations before treatment. Erdafitinib blocks FGFR signalling involved in cancer-cell growth, but it can also affect normal tissues.

How to use

Take Erdafitinib 4mg exactly as directed by the oncologist. Dose adjustments depend on phosphate level, side effects, eye findings, and response.

How it works

Erdafitinib inhibits FGFR tyrosine kinases, reducing growth signals in cancers driven by susceptible FGFR alterations.

Common side effects

Side effects may include mouth sores, diarrhea, dry mouth, nail changes, skin dryness, eye problems, high phosphate, fatigue, taste changes, decreased appetite, and hand-foot symptoms.

Important information

Tumor FGFR testing is required. Keep eye exams and lab monitoring. Report blurred vision, eye pain, severe diarrhea, mouth sores, nail infection, or pregnancy immediately.